Illumina HiSeq 2500 paired end sequencing; GSM3504538: 54-12 T2 r1; Homo sapiens; RNA-Seq

54-12 T2 r1

FSHD myoblasts show a suppression of ESRRA and PPARGC1A during myogenesis Overall design: FSHD Myoblasts 54-2, 54-12, 54-A5, 16A and 12A and matched controls 54-6, 54-A10, 16U and 12U were plated at 312,000 cells per 12 well plate in proliferation media and cultured for 48 hours or until 100% confluent, then induced to differentiate for 3.5 days, samples were taken at 8 time points during differentation for 54-6 and 54-12 and at confluency and terminal differentiation in the remaining lines. RNA-sequencing was performed on high quality (RIN > 8.0) DNA free RNA.

RNA-seq of FSHD and control immortalised myoblasts II

Submitted on 08-DEC-2018

RNA was isolated at 8 time points: T1: 0 mins (confluent proliferating myoblasts); T2: 440 mins (54-6 alignment), T3: 530 mins (54-12 alignment), T4: 1355 mins (54-6 initiation of fusion), T5: 1505 mins (54-12 initiation of fusion), T6: 1860 mins (54-6 myotube formation), T7: 2165 mins (54-12 myotube formation) and T8: 5040 mins (myotube maturation) using miRNeasy kit (Qiagen, Manchester, UK) including DNase digestion from each cell line in triplicate. RNA quality/concentration were checked by LabChip Bioanalyzer (RIN>8.0) and Nanodrop. RNA-seq libraries were prepared using the Agilent sureselect stranded RNAseq protocol, which allows polyA selection but was modified to work with ribodepletion. Libraries were sequenced on an Illumina HiSeq2500.

RNA-seq of FSHD and control immortalised myoblasts II

Submitter Supplied Information

Samples